Director/PDMR Shareholding

RNS Number : 9862Y

Roquefort Therapeutics PLC

19 January 2022

 

19 January 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:

Name	Number of Ordinary Shares	Average Price Paid Per Share	Total Consideration Paid
Stephen West	150,000	10.36 pence	£15,542.10

Following the above purchase of shares, Mr West holds interests in the following Company securities:

Name	Number of Ordinary Shares Held	% of Issued Share Capital	Number of Warrants Held
Stephen West	4,550,000	6.33 %	7,500,000

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

 

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman)	[phone]
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale Optiva Securities Limited (Broker)	[phone]
Christian Dennis	[phone]

For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @RoquefortTherap   on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd ("LYRAMID"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19.  Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation. 

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). LYRAMID's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stephen West
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Roquefort Therapeutics plc
b)	LEI	254900P4SISIWOR9RH34
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15
b)	Nature of the transaction	Purchase of 150,000 ordinary shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		10.31 pence per share 10.46 pence per share	100,000   50,000
d	Aggregated information - Aggregated volume - Price	-  150,000 -  10.36p
e)	Date of the transactions	19 January 2022
f)	Place of the transactions	London Stock Exchange (XLON); Main Market

 

END

 

 

DSHBDGDBUUBDGDC